NIH Funding Opportunities

Opportunities are posted in the order they are received and may not appear by due date. Please review accordingly.

Sidebar

NIAID: Innovation for HIV Vaccine Discovery (R01) Clinical Rial Not Allowed)

 The purpose of this reissued Notice of Funding Opportunity (NOFO) is to support high-risk, high-impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high-risk, high-impact nature of this research, this NOFO supports a Go/No-Go approach to funding high risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated “Go/No-Go” criteria by the end of Year 2.

PAR-23-169

Application Due Date: August 2, 2023

NIH- Synthetic Nucleic Acid Platforms for HIV-1 (SNAPH): (R61/R33 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to advance synthetic nucleic acid platforms for the rapid development and iterative testing of active and passive immunization strategies for HIV prevention, treatment, and cure. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the second phase will depend on the successful completion of milestones.

RFA-AI-23-026

Application Due Date: August 2, 2023

NIH- Notice of Special Interest (NOSI): Opportunities for HIV Cure Interventions at the Time of ART Initiation

This Notice of Special Interest (NOSI) serves to identify new opportunities for cure strategies during active HIV infection at or near the start of antiretroviral therapy (ART) or as a potential replacement for conventional ART, with the ultimate goal of achieving a sustained ART-free HIV remission.

NOT-AI-22-072

First Available Due Date: January 07, 2023
Expiration Date: September 08, 2025

NIH- Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed)

Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.

RFA-CA-22-056

Open Date (Earliest Submission Date): November 15, 2022
Expiration Date: December 16, 2023

NIH- Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed)

Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.

RFA-CA-22-057

Open Date (Earliest Submission Date): November 15, 2022
Expiration Date: December 16, 2023


NIDA REI- Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA)?is a part of?NIDA’s Racial Equity Initiative (REI).This FOA invites R01 applications to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to improve outcomes related to substance misuse, with a goal of preventing, reducing, or eliminating disparities in racial and ethnic minority populations in substance use, addiction, and related health consequences, including HIV. Community engaged research can facilitate rapid advances in this scientific area by ensuring relevant research questions with immediate applicability.

RFA-DA-23-032

Open Date (Earliest Submission Date): October 14, 2022
Due Date: November 14, 2022


NIAID: Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).

PAR-22-186

First Available Due Date: December 07, 2022

Expiration Date: December 08, 2024


NIAID - Notice of Special Interest (NOSI): Towards Developing a Cure for HBV in HIV/HBV Co-Infection

The Notice of Special Interest (NOSI) seeks to fill scientific gaps needed to (a) inform HBV cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts; and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a cure in HIV and HBV co-infected individuals.

NOT-AI-22-043

First Available Due Date: September 05, 2022

Expiration Date: May 08, 2025


NIAID- Notice of Special Interest (NOSI): Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP)

The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.

NOT- AI-22-042

First Available due date: September 7, 2022

Expiration Date: May 8, 2025

At a Glance